share_log

石藥集團:截至二零二四年三月三十一日止月份之股份發行人的證券變動月報表

CSPC PHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024

香港交易所 ·  Apr 2 05:38
Summary by Moomoo AI
石藥集團有限公司於2024年4月2日向香港交易及結算所有限公司提交了最新的證券變動月報表,涵蓋截至2024年3月31日的情況。報告顯示,根據2015年購股權計劃,公司於3月底的普通股股份期權結存數量為50,000,000,與上月底持平,並無新增股份。該股份期權計劃於2015年12月9日生效,至今仍然有效。本月內沒有行使任何股份期權,因此沒有因行使期權而得到的資金。報告由董事翟健文呈交。
石藥集團有限公司於2024年4月2日向香港交易及結算所有限公司提交了最新的證券變動月報表,涵蓋截至2024年3月31日的情況。報告顯示,根據2015年購股權計劃,公司於3月底的普通股股份期權結存數量為50,000,000,與上月底持平,並無新增股份。該股份期權計劃於2015年12月9日生效,至今仍然有效。本月內沒有行使任何股份期權,因此沒有因行使期權而得到的資金。報告由董事翟健文呈交。
Petrochemical Group Limited filed with Hong Kong Trading and Settlement Limited on 2 April 2024 with Hong Kong Trading and Settlement Limited, covering the situation as of 31 March 2024. The report shows that under the 2015 Share Option Plan, the Company had a total of 50,000,000 ordinary share options at the end of March, which was flat with the end of the previous month, with no new shares added. The share option scheme became effective on 9 December 2015 and remains in force to this day. No stock options were exercised during the month, so no funds were received as a result of the exercise of the option. The report was presented by the Director, Chien-Wen Chai.
Petrochemical Group Limited filed with Hong Kong Trading and Settlement Limited on 2 April 2024 with Hong Kong Trading and Settlement Limited, covering the situation as of 31 March 2024. The report shows that under the 2015 Share Option Plan, the Company had a total of 50,000,000 ordinary share options at the end of March, which was flat with the end of the previous month, with no new shares added. The share option scheme became effective on 9 December 2015 and remains in force to this day. No stock options were exercised during the month, so no funds were received as a result of the exercise of the option. The report was presented by the Director, Chien-Wen Chai.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more